NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»03/03/2010 [Company watch]
Generex Is Granted a China Patent for Cancer Vaccine 1 comment

Generex Biotechnology (NSDQ: GNBT) announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer.

 

Generex Biotechnology (NSDQ: GNBT) announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. The patent was granted to Antigen Express, the Generex subsidiary that is developing the vaccine.

 

According to Generex, it is actively seeking either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas.

 

Recently, Generex reported interim results, taken at the 13-month mark, from a Phase II trial of an Ii-Key modified peptide vaccine for breast cancer patients who are at high risk of relapse. Although the control arm experienced a 7% relapse rate, there were no relapses in the Ii-Key peptide arm in the first 13 months.

 

Generex is a drug delivery company that develops liquid formulations of drugs that are administered using the companys RapidMist device. Drugs are delivered through the oral cavity, where they are absorbed through the lining of the inner mouth with no deposit in the lungs.

 

Antigen Express is a wholly owned subsidiary of Generex. It develops immunotherapeutics that treat malignant, infectious, allergic, and autoimmune diseases.

 

In October 2007, Generex / Antigen Express said it would begin clinical trials of the Ii-Key modified peptide vaccine in China, though the company has not made any announcements about the China trial in the last two and a half years.

 


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.